Clinical trials: Hepatic Neoplasm
Liver Transplantation, No-touch Technique
Impact of "No-touch" Technique on the Outcome of Liver Transplantation for Hepatocellular Carcinoma
The "no-touch" technique has been one of the most important principles of oncological surgery and aimed to prevent seeding and tumor cell dissemination.
- Conditions
- Liver Transplantation, No-touch Technique, Hepatocellular Carcinoma
- Trial name
- NCT06331273
- Testing
- Liver transplantation with "No-touch" technique
- Volunteers
- 800 people
- Sponsor
- Zhejiang University
Transarterial Chemoembolization, Hepatocellular Carcinoma
TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC
Purpose：explore the effectiveness and safety of transarterial chemoembolization (TACE) plus Hepatic Arterial Infusion Chemotherapy (HAIC) with oxaliplatin and raltitrexed for Barcelona stage C hepatocellular carcinoma (HCC)
- Trial name
- OXRI (NCT04597970)
- Testing
- cTACE-HAIC
- Volunteers
- 66 people
- Sponsor
- Peking University Cancer Hospital & Institute
Hepatocellular Carcinoma
Combined Therapy for Hepatocellular Carcinoma >3-<5 cm
The purpose of this study is to compare the safety and efficacy of combined therapy with conventional transarterial chemoembolization (cTACE) + microwave ablation (MWA) versus only TACE or MWA for treatment of hepatocellular…
- Trial name
- NCT04721470
- Testing
- Combined therapy, Microwave ablation, Transarterial chemoembolization
- Volunteers
- 278 people
- Sponsor
- Zagazig University
Advanced Biliary Tract Cancer
HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC
Hepatic arterial infusion chemotherapy (HAIC) deliver high concentration of chemotherapeutic agents directly to the liver tumor, was proved to be effective for intrahepatic and perihilar cholangiocarcinoma.
- Trial name
- NCT04217954
- Testing
- OXA, 5-FU and bevacizumab plus Toripalimab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Peking University
Hepatic Tumor, Renal Tumor
Evaluation of the Reproducibility of Ablation Volumes at One Month After Microwave Treatment Compared to the Manufacturer's Abacus: on the Kidney, Liver and Lung
Microwave thermal ablation (MO) is recognized as an alternative to surgery for the local-regional treatment of primary and secondary hepatic and renal tumors and for secondary pulmonary tumors in patients at anesthetic and/or…
- Trial name
- Ablation (NCT04072224)
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Hepatocellular Carcinoma
Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
This phase I trial is studying the safety and best dose of GC33 and Sorafenib in combination in patients with advanced or metastatic liver cancer.
- Trial name
- NCT00976170
- Testing
- GC33(RO5137382), Sorafenib
- Where
- 7 sites in United States, Taiwan
- Volunteers
- 42 people
- Sponsor
- Chugai Pharmaceutical
Colorectal Cancer
Role of MRI in the Evaluation of Hepatic Metastases of Colorectal Cancer
This study wants to evaluate the use of MRI in the managemente of mCRC with liver only metastases.
- Trial name
- RMN-CRC (NCT05950503)
- Testing
- Hepatic MRI
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Hepatocellular Carcinoma
A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
The purpose of this study is to evaluate the safety and tolerability of BMS-986183 in patients with liver cancer.
- Trial name
- NCT02828124
- Testing
- BMS-986183, Nivolumab
- Where
- 4 sites in Canada, Singapore and 2 more
- Volunteers
- 25 people
- Sponsor
- Bristol-Myers Squibb
Carcinoma, Hepatocellular, Liver Dysfunction
Evaluation of Remnant Liver Function Using Primovist-enhanced MRI Before Resection/Ablation of Hepatocellular Carcinoma
The purpose of this study is to determine whether the global and segmental hepatic uptake and excretion of Gd-EOB-DTPA on Gd-EOB-DTPA-enhanced liver MRI correlates with standard liver function test results in the patients with…
- Trial name
- LiFE (NCT01490203)
- Testing
- Gd-EOB-DTPA, MRI
- Where
- 4 sites in South Korea
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Hepatic Carcinoma, Chemoembolizaton
Transradial Versus Transfemoral Arterial Access in Liver Cancer Embolization: Randomized Trial to Assess Patient Outcomes and Satisfaction (BEST ACCESS Trial).
To evaluate the safety, advantages, and appropriateness of performing transarterial hepatic emobolization of liver cancer via arterial access from the radial artery versus conventional transfemoral arterial access.
- Conditions
- Hepatic Carcinoma, Chemoembolizaton, Transarterial Embolization
- Trial name
- ACCESS (NCT03163186)
- Testing
- Transarterial embolization
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Medical University of South Carolina
Carcinoma, Hepatocellular
Proton Radiotherapy Versus Radiofrequency Ablation for Patients With Medium or Large Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common cancers in Taiwan, where chronic viral hepatitis is common. Patients with HCC typically have impaired liver function because of virus- or alcohol- induced cirrhosis and…
- Trial name
- NCT02640924
- Testing
- Proton radiotherapy, Radiofrequency Ablation
- Where
- Taiwan
- Volunteers
- 166 people
- Sponsor
- Chang Gung Memorial Hospital
Liver Carcinoma
Radiofrequency-responsive Layered Double Hydroxides for Enhanced Arterial Embolization and Thermal Immunotherapy in Hepatocellular Carcinoma
Liver cancer is one of the most common malignant tumors and the third leading cause of cancer-related deaths globally. Recent epidemiological studies show that in China, liver cancer ranks fourth in incidence and second in…
- Trial name
- NCT06966986
- Where
- China
- Volunteers
- 130 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Hepatocellular Carcinoma
[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
There is great need for new therapeutic options for patients with hepatocellular carcinoma (HCC). This proposal will assess the feasibility of a novel theranostic approach to HCC using [68Ga]DOTATATE, a recently approved positron…
- Trial name
- NCT03648073
- Testing
- [68Ga]DOTATATE-PET/MRI
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Alabama at Birmingham
Liver Cancer, Liver Failure
Quantitative MRI and Outcomes of Liver Resection
The present observational study aims to assess the benefit of this quantitative multiparametric magnetic resonance imaging (MRI) in clinical practice, to quantify future liver remnant performance, and to accurately predict the…
- Conditions
- Liver Cancer, Liver Failure, Bile Leak, Liver Metastases
- Trial name
- NCT06181318
- Testing
- Multiparametric MRI scan of the liver
- Volunteers
- 33 people
- Sponsor
- University Hospital Heidelberg
Advanced Hepatocellular Carcinoma
Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma
This is a prospective, single-arm, phase Ib/II trial . The objective of this study is to evaluate the efficacy and safety of adebrelimab, camrelizumab plus apatinib as first-line therapy in patients with advanced hepatocellular…
- Trial name
- NCT05924997
- Testing
- adebrelimab, camrelizumab plus apatinib
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepatocellular Carcinoma, Renal Cell Carcinoma
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
Study Design and Investigational Plan: This is an open-label Phase 1/2 study to assess the safety and tolerability of combination PD-1 inhibitor (APL-501 or nivolumab) administered concomitantly with c-Met inhibitor (APL-101), to…
- Trial name
- NCT03655613
- Testing
- APL-501, APL-101, Nivolumab
- Where
- 9 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Apollomics (Australia) Pty. Ltd.
Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced
Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
A study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme in patients with histologically proven advanced malignant pleural mesothelioma (MPM), advanced peritoneal mesothelioma (in dose escalation cohort…
- Conditions
- Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced, Non-squamous Non-small Cell Lung Carcinoma, Uveal Melanoma
- Trial name
- TRAP (NCT02029690)
- Testing
- ADI-PEG 20
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 85 people
- Sponsor
- Polaris Group
Arteriovenous Malformation, Hemangioma
Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEB
This is an open-label whole-body PET/CT study for investigation of radiation dosimetry, plasma pharmacokinetics, biodistribution, safety and diagnostic performance of 68Ga-NEB in healthy volunteers and patients with suspected…
- Conditions
- Arteriovenous Malformation, Hemangioma, Neoplasms Lymph Nodes, Lymphedema
- Trial name
- NCT02496013
- Testing
- 68Ga-NEB
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Hepatocellular Carcinoma
Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients
This is a single-arm, open-label and post-authorization study to evaluate the safety and efficacy profile of sorafenib and to evaluate Child-Pugh status progression in subjects with advanced HCC treated with sorafenib in Taiwan.
- Trial name
- HATT (NCT01098760)
- Testing
- Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment
- Where
- 7 sites in Taiwan
- Volunteers
- 151 people
- Sponsor
- Bayer
Hepatocellular Carcinoma (HCC)
SBRT Versus Surgical Resection for Small HCC
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related incidence and mortality in China and represents a major public health challenge.
- Trial name
- NCT07381660
- Testing
- Stereotactic body radiotherapy (SBRT), Resection
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.